
News|Articles|February 13, 2019
Xospata for Relapsed or Refractory AML
Author(s)Drew Boxler
Advertisement
Xospata (gilteritinib, Astellas)
Indications: Adult patients with relapsed or refractor acute myeloid leukemia (AML) with an FLT3 mutation.
Dosage: 120 mg orally once-daily; 40 mg tablets
Contraindications: Hypersensitivity to gilteritinib or any of the excipients. Naphylactic reactions have been observed in clinical trials.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Guideline Refines Approach to Migraine Prevention in Adults
2
Digital Outreach Improves Statin Adherence in High-Risk Patients
3
Pharmacy Leaders Set Priorities for Global Primary Care Integration
4
Recombinant Shingles Vaccine May Lower Cardiovascular Risk
5































